Home›Explore peptides›Retatrutide
Retatrutide
Not approved anywhere, and Lilly isn't expected to file in the US until roughly early 2027 — but the peer-reviewed Phase 2 trial data is real and strong, and it's already the target of real FDA warning letters to online sellers.
Evidence grade B: what kinds of studies support the claims on this page, with limits. It is not a verdict on any product. How we grade
On this page
In brief
Should you care? Yes if you've seen it marketed as the "next" weight-loss peptide — the trial numbers are real, but that doesn't make buying it from an unapproved online seller legal or safe, and real Australian hospital cases in 2026 show exactly what can go wrong.The short version
- A "triple agonist" — acts on GIP, GLP-1 and glucagon receptors, one mechanism beyond tirzepatide's two.
- Real peer-reviewed Phase 2 data shows the largest weight-loss numbers reported for any drug in this class so far.
- Not approved anywhere, and already the subject of real FDA warning letters to online sellers.
- In Australia, at least seven hospitalizations for acute liver toxicity and one near-fatal torn oesophagus have been linked to products sold under this name since January 2026 — one tested sample contained no retatrutide at all, just an undisclosed, oversized dose of semaglutide.
What it is
Retatrutide is a "triple agonist" — it acts on GIP, GLP-1 and glucagon receptors, developed by Eli Lilly, one mechanism further than tirzepatide's dual GIP/GLP-1 action.
The trial evidence
The peer-reviewed Phase 2 trial (Jastreboff et al., N Engl J Med 2023;389:514-526, DOI 10.1056/NEJMoa2301972, PMID 37366315) enrolled 338 adults with obesity over 48 weeks and found dose-dependent weight loss up to a mean 24.2% at the highest dose versus placebo. Lilly has since announced — via company press release, not yet peer-reviewed — large positive topline results from Phase 3 trials including TRIUMPH-1. Company-reported numbers are real information, but a meaningfully weaker form of evidence than a published, peer-reviewed trial, and worth treating as such rather than as settled.
Regulatory status
Not approved anywhere. Lilly has said it expects to file for FDA approval in the US around early 2027. In the meantime, FDA has issued real warning letters to online sellers marketing unapproved retatrutide as a research chemical — part of a documented 2026 sweep naming more than a dozen vendors, several of which are also logged on this site's own Register.
Why it's already sold online
As an investigational compound with strong publicized trial numbers, retatrutide is a predictable target for grey-market "research chemical" sale well before any approval — the same pattern this site has documented for BPC-157 and semaglutide-adjacent compounds. None of the sellers behind those warning letters are listed as vetted anywhere on this site.
Australia: real, escalating harm from a counterfeit product
Australia in 2026 supplies the clearest real-world demonstration yet of what "not knowing what's in the vial" actually means. Victoria's chief health officer issued a public health alert after the state's health department identified six cases, since January 2026, of acute liver toxicity in people who had used an unapproved product labelled "retatrutide," bought online, through social contacts, or via social media. A seventh case followed by late August 2026, prompting the Therapeutic Goods Administration (TGA) to say publicly it was investigating whether a contaminated manufacturing batch was responsible. None of the affected products has been traced to a single named seller in the public record.
A separate case disclosed by the TGA in September 2026 shows the risk isn't limited to liver damage. A patient using a product sold as retatrutide suffered uncontrollable vomiting severe enough to tear the oesophagus — an injury that is close to universally fatal without prompt treatment. Laboratory testing of the product afterward found it contained no retatrutide whatsoever: instead, an undeclared dose of semaglutide roughly eight times the concentration the TGA has found in legitimate semaglutide products. The patient had no way of knowing that before injecting it, because nothing sold under a research-chemical or grey-market label in Australia (or anywhere else) is tested before it reaches a buyer. The TGA's own chief medical adviser, Professor Robyn Langham, put the underlying problem plainly: the biggest risk with an unapproved peptide product is simply not knowing what's actually in the vial, at what dose, or whether it's even sterile.
Retatrutide's own regulatory timeline, above, means an approved, tested version of this drug does not exist anywhere yet and won't for at least another year. Every product sold under its name today — in Australia or elsewhere — is by definition unregulated, and these cases show that "sold as retatrutide" is no guarantee the vial contains retatrutide at all. See the TGA's compounding ban and enforcement record for how Australia is responding to unapproved peptides generally, and vendor red flags for what to look for before trusting any unapproved-peptide listing, in any country.
What you can do next
References
- Jastreboff et al., "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial," N Engl J Med 2023;389:514-526, DOI 10.1056/NEJMoa2301972, PMID 37366315.
- Eli Lilly investor press releases on TRIUMPH Phase 3 topline results, 2026 — company-reported, not yet peer-reviewed.
- FDA warning letters to online retatrutide sellers, 2026 (see the Register for specific vetted findings).
- Victorian Department of Health, public health alert, "Toxicity linked to unapproved peptide product labelled Retatrutide," health.vic.gov.au, first issued ~19-20 June 2026 (six cases since January 2026); ABC News, "Melbourne woman suffers acute liver failure after using knock-off drug," 20 June 2026, and "Doctors fear possible contaminated counterfeit peptide batch after seventh case of acute liver damage," 24 August 2026 — both abc.net.au; independently corroborated by the Victorian Department of Health's own public social-media statement (@VicGovDH) confirming the six-case count and by contemporaneous trade coverage in Medical Republic and RACGP's newsGP.
- ABC News, "Patient suffers torn oesophagus after using unapproved peptide, prompting fresh warnings," 14 September 2026 — abc.net.au, reporting the TGA's own disclosure of the case, its laboratory finding of undeclared semaglutide at roughly eight times the concentration found in TGA-assessed legitimate semaglutide products, and an on-the-record quote from TGA Chief Medical Adviser Professor Robyn Langham AM; independently corroborated by RACGP newsGP ("TGA issues warning against unapproved peptides"), Medical Republic, and separate wire-style pickups (AOL, NewsBytes, SSBCrack, Newsy Today) reporting the same case details, contamination finding and quote.